Goldman Sachs analyst Bruno Amorim maintains Cosan (NYSE:CSAN) with a Neutral and raises the price target from $15.6 to $18.3.
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
In the latest quarter, 14 analysts provided ratings for Apellis Pharmaceuticals (NASDAQ:APLS), showcasing a mix of bullish and…